{"id":5479,"date":"2026-01-17T01:06:28","date_gmt":"2026-01-16T22:06:28","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=5479"},"modified":"2026-01-17T01:06:30","modified_gmt":"2026-01-16T22:06:30","slug":"atossa-therapeutics-receives-fda-orphan-drug-designation-for-z-endoxifen-for-the-treatment-of-duchenne-muscular-dystrophy","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/fr\/atossa-therapeutics-receives-fda-orphan-drug-designation-for-z-endoxifen-for-the-treatment-of-duchenne-muscular-dystrophy\/","title":{"rendered":"Le Atossa Therapeutics obtient la d\u00e9signation de m\u00e9dicament orphelin FDA pour le (Z)-Endoxifen dans le traitement de la dystrophie musculaire de Duchenne."},"content":{"rendered":"<p class=\"wp-block-paragraph\">Atossa Therapeutics a annonc\u00e9 que le Bureau du d\u00e9veloppement des produits orphelins de la Food and Drug Administration am\u00e9ricaine (\u201c FDA \u201d) a accord\u00e9 la d\u00e9signation de m\u00e9dicament orphelin \u00e0 (Z)-endoxifen pour le traitement de la dystrophie musculaire de Duchenne (\u201c DMD \u201d). &gt;&gt; <strong>Apprendre encore plus:<\/strong> <a href=\"https:\/\/dmdwarrior.com\/fr\/atossa-therapeutics-receives-fda-rare-pediatric-disease-designation-for-z-endoxifen-for-duchenne-muscular-dystrophy\/\" target=\"_blank\" data-type=\"link\" data-id=\"https:\/\/dmdwarrior.com\/atossa-therapeutics-receives-fda-rare-pediatric-disease-designation-for-z-endoxifen-for-duchenne-muscular-dystrophy\/\" rel=\"noreferrer noopener\">Atossa Therapeutics re\u00e7oit la d\u00e9signation de maladie p\u00e9diatrique rare FDA pour (Z)-Endoxifen<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u201c En plus de la d\u00e9signation de maladie p\u00e9diatrique rare pr\u00e9c\u00e9demment obtenue, la d\u00e9signation de m\u00e9dicament orphelin pour (Z)-endoxifen dans la dystrophie musculaire de Duchenne est une \u00e9tape importante pour Atossa alors que nous poursuivons le d\u00e9veloppement de (Z)-endoxifen pour cette maladie grave et invalidante \u201d, a not\u00e9 Steven C. Quay, MD, Ph.D., pr\u00e9sident et chef de la direction de Atossa Therapeutics.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Le projet Atossa pr\u00e9voit de continuer \u00e0 collaborer avec le projet FDA \u00e0 mesure qu&#039;il progresse dans ses efforts de d\u00e9veloppement et fournira des mises \u00e0 jour le cas \u00e9ch\u00e9ant.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Suivre cette page<\/strong>&nbsp;&gt;&gt;&gt;&nbsp;<a href=\"https:\/\/dmdwarrior.com\/fr\/dmd-therapies\/\" target=\"_blank\" rel=\"noreferrer noopener\">Tous les essais cliniques pour la dystrophie musculaire de Duchenne<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Atossa Therapeutics, announced that the U.S. Food and Drug Administration (&#8220;FDA&#8221;) Office of Orphan Products Development has granted Orphan Drug Designation to (Z)-endoxifen for the treatment of Duchenne muscular dystrophy (&#8220;DMD&#8221;). >> Learn More: Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen &#8220;In addition to the previously received Rare Pediatric Disease designation, Orphan [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":5480,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[281],"tags":[461,462,464,463],"class_list":["post-5479","post","type-post","status-publish","format-standard","has-post-thumbnail","category-press-releases","tag-z-endoxifen","tag-atossa-therapeutics","tag-endoxifen","tag-tamoxifen"],"_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/posts\/5479","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/comments?post=5479"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/posts\/5479\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/media\/5480"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/media?parent=5479"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/categories?post=5479"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/tags?post=5479"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}